Impact of NSAID and triptan use on developing chronic migraine: Results from the american migraine prevalence and prevention (AMPP) study

Headache

Volumn 53, Issue 10, 2013, Pages 1548-1563

  Lipton, Richard B ^a   Serrano, Daniel ^b   Nicholson, Robert A ^c   Buse, Dawn C ^a   Runken, M Chris ^d   Reed, Michael L ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b VEDANTA RESEARCH   (United States)

^c Mercy Clinic Headache Center   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

acute treatment; chronic migraine; migraine; migraine progression; nonsteroidal anti inflammatory drug; triptan

Indexed keywords

ALMOTRIPTAN; ELETRIPTAN; FROVATRIPTAN; IBUPROFEN; KETOPROFEN; KETOROLAC; NAPROXEN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; RIZATRIPTAN; SUMATRIPTAN; TRIPTAN DERIVATIVE; ZOLMITRIPTAN;

ADULT; ARTICLE; DISEASE COURSE; DOSE RESPONSE; DRUG USE; EPISODIC MIGRAINE; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHYSICAL DISABILITY; POPULATION RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; STATISTICAL SIGNIFICANCE; TERTIARY HEALTH CARE; TRANSFORMED MIGRAINE;

ACUTE TREATMENT; CHRONIC MIGRAINE; MIGRAINE; MIGRAINE PROGRESSION; NONSTEROIDAL ANTI-INFLAMMATORY DRUG; TRIPTAN;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PIPERIDINES; POPULATION SURVEILLANCE; PREVALENCE; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SUMATRIPTAN; TRYPTAMINES; UNITED STATES;

EID: 84888304059     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/head.12201     Document Type: Article

References (41)

1. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007; 68: 343-349.
2. International Headache Society. The international classification of headache disorders, 2nd edition. Cephalalgia. 2004; 24 (Suppl. 1): 9-160.
3. Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006; 26: 742-746.
4. Buse DC, Manack AN, Fanning K, et al. Chronic migraine prevalence, disability, and sociodemographic factors: Results from the American Migraine Prevalence and Prevention study. Headache. 2012; 52: 1456-1470.
5. Natoli JL, Manack A, Lipton RB, et al. Global prevalence of chronic migraine: A systematic review. Cephalalgia. 2010; 30: 599-609.
6. Lipton RB,. Tracing transformation: Chronic migraine classification, progression, and epidemiology. Neurology. 2009; 72 (5 Suppl.): S3-S7.
7. Grosberg BM, Dodick DW, Sheftell FD, et al. Assessing educational needs of American Headache Society (AHS) members in the field of chronic migraine (CM). Poster presented at the European Headache and Migraine Trust International Congress, Nice, France, October 2010.
8. Bigal ME, Rapaport AM, Lipton RB, et al. Assessment of migraine disability using the Migraine Disability Assessment (MIDAS) questionnaire: A comparison of chronic migraine with episodic migraine. Headache. 2008; 43: 336-342.
9. Bigal ME, Serrano D, Reed M, Lipton RB,. Chronic migraine in the population: Burden, diagnosis and satisfaction with treatment. Neurology. 2008; 71: 559-566.
10. Bussone G, Usai S, Grazzi L, et al. Disability and quality of life in different primary headaches: Results from Italian studies. Neurol Sci. 2004; 25: S105-S107.
11. Meletiche DM, Lofland JH, Young WB,. Quality-of-life differences between patients with episodic and transformed migraine. Headache. 2001; 41: 573-578.
12. Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011; 31: 301-315.
13. Buse DC, Manack A, Serrano D, et al. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010; 81: 428-432.
14. Bigal ME, Serrano D, Buse D, Scher AI, Stewart WF, Lipton RB,. 2008 Wolff Award of the American Headache Society. Migraine medications and evolution from episodic to chronic migraine: A longitudinal population-based study. Headache. 2008; 48: 1157-1168.
15. Ashina S, Lyngberg A, Jensen R,. Headache characteristics and chronification of migraine and tension-type headache: A population-based study. Cephalalgia. 2010; 30: 943-952.
16. Bigal ME, Lipton RB,. Excessive acute migraine medication use and migraine progression. Neurology. 2008; 71: 1821-1828.
17. Couch JR, Lipton RB, Stewart WF, et al. Head or neck injury increases the risk of chronic daily headache: A population-based study. Neurology. 2007; 69: 1169-1177.
18. Scher AI, Stewart WF, Ricci JA, et al. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain. 2003; 106: 81-89.
19. Ashina S, Serrano D, Lipton RB, et al. Depression and risk of transformation of episodic to chronic migraine. J Headache Pain. 2012; 13: 615-624.
20. Bigal ME, Rapoport AM, Sheftell FD, et al. Transformed migraine and medication overuse in a tertiary headache centre: Clinical characteristics and treatment outcomes. Cephalalgia. 2004; 24: 483-490.
21. Rapoport A, Stang P, Gutterman DL,. Analgesic rebound headache in clinical practice: Data from a physician survey. Headache. 1996; 36: 14-19.
22. Silberstein S, Diener HD, Lipton RB, et al. Epidemiology, risk factors, and treatment of chronic migraine: A focus on topiramate. Headache. 2008; 48: 1087-1095.
23. Zwart JA, Dyb G, Hagen K, et al. Analgesic overuse among subjects with headache, neck, and low-back pain. Neurology. 2004; 62: 1540-1544.
24. Smith TR, Sunshine A, Stark SR, et al. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2005; 45: 983-991.
25. Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: A randomized trial. JAMA. 2007; 297: 1443-1454.
26. Cleves C, Tepper SJ,. Sumatriptan/naproxen sodium combination for the treatment of migraine. Expert Rev Neurother. 2008; 8: 1289-1297.
27. Burstein R, Collins B, Jakubowski M,. Defeating migraine pain with triptans: A race against the development of cutaneous allodynia. Ann Neurol. 2004; 55: 19-26.
28. Burstein R, Jakubowski M,. Analgesic triptan action in an animal model of intracranial pain: A race against the development of central sensitization. Ann Neurol. 2004; 55: 27-36.
29. Manack AB, Buse DC, Serrano D, et al. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology. 2011; 76: 711-718.
30. Waeber C, Moskowitz MA,. Migraine as an inflammatory disorder. Neurology. 2005;(Suppl. 2) 64: S9-S15.
31. Lipton RB, Stewart WF, Simon D,. Medical consultation for migraine: Results from the American Migraine Study. Headache. 1998; 38: 87-96.
32. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF,. Migraine diagnosis and treatment: Results from the American Migraine Study II. Headache. 2001; 41: 638-645.
33. Liebenstein M, Bigal M, Sheftell F, Tepper S, Rapoport A, Lipton R,. Validation of the chronic daily headache questionnaire (CDH-Q). Headache. 2007; 47: 760-761.
34. Silberstein SD, Lipton RB, Sliwinski M,. Classification of daily and near-daily headaches: Field trial of revised IHS criteria. Neurology. 1996; 47: 871-875.
35. Lipton RB, Stewart WF, Sawyer J, Edmeads JG,. Clinical utility of an instrument assessing migraine disability: The Migraine Disability Assessment (MIDAS) questionnaire. Headache. 2001; 41: 854-861.
36. Stewart WF, Lipton RB, Dowson AJ, Sawyer J,. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001; 56 (6 Suppl. 1): S20-S28.
37. Lipton RB, Bigal ME, Ashina S, et al. Cutaneous allodynia in the migraine population. Ann Neurol. 2008; 63: 148-158.
38. Little RJA, Rubin DB,. Statistical Analysis with Missing Data, 2nd edn. New York: John Wiley; 2002.
39. Schafer JL,. Analysis of Incomplete Multivariate Data. London: Chapman & Hall; 1997.
40. Serrano D, Manack AB, Reed ML, et al. Cost and predictors of lost productive time in chronic migraine and episodic migraine: Results from the American Migraine Prevalence and Prevention (AMPP) study. Value Health. 2013; 16: 31-38.
41. Buse DC, Pearlman SH, Reed ML, Serrano D, Ng-Mak DS, Lipton RB,. Opioid use and dependence among persons with migraine: Results of the AMPP study. Headache. 2012; 52: 18-36.